Effect of intralipid infusion on serum high- and low-density lipoprotein cholesterol, lecithin: Cholesterol acyltransferase, and lipoprotein lipase in tumor-bearing rats
- 41 Downloads
We compared the effects of 0.45% normal saline (NS), 5% Intralipid® (IL), and 16.7% glucose (Glu) infusions on total serum triglycerides and cholesterol, serum high-(HDL-c) and low-density lipoprotein cholesterol (LDL-c), and activity of serum lecithin: cholesterol acyltransferase (LCAT), and serum lipoprotein lipase (LPL) in rats implanted with a fibrosarcoma. In tumor-bearing rats given NS, a two-fold increase in total serum cholesterol, a four-fold increase in LDL-c, and a five-fold decrease in the HDL-c/LDL-c ratio were observed compared to tumor-free rats. In tumor-bearing rats administered IL, a two-fold increase in total serum triglyceride and cholesterol, a three-fold increase in HDL-c and HDL-c/LDL-c ratio, and a two-fold increase in LPL activity were observed compared to tumor-bearing rats administered NS. In tumor-bearing rats administered Glu, a two-fold decrease in total serum cholesterol, a two-fold decrease in HDL-c, and a three-fold decrease in LDL-c were observed compared to tumor-bearing rats administered NS. Tumor weights and LCAT activity did not differ significantly between treatment groups. Previous results have demonstrated that lipophilic compounds that interact with plasma lipoproteins have altered pharmacological effects when administered with IL. Therefore, this study suggests that IL infusions alter the HDL-c/LDL-c ratio and could affect the pharmacological behavior of anticancer compounds that predominantly distribute into the LDL fraction upon entrance into the bloodstream.
Key wordsIntralipid lipoproteins fibrosarcoma
Unable to display preview. Download preview PDF.
- 5.Tashiro, T., Mashima, Y., Yamamori, H., Horibe, K., Nishizawa, M., Sanada, M., and Okui, K., J. parental ent. Nutr.15 (1991) 546.Google Scholar
- 15.Joly, V., Farinotti, R., Saint-Julien, L., Cheron, M., Carbon, C., and Yeni, P., Antimicrob. Ag. Chemother.38 (1994) 177.Google Scholar
- 19.Grossie, V. B., Nishioka, K., Ota, D. M., and Martin, R. G., Cancer Res.46 (1986) 3463.Google Scholar
- 20.Steiger, E., Vars, E. M., and Dudrick, S. J., Archs. Surg.104 (1972) 330.Google Scholar
- 21.Turco, S., and King, R. E., in: Sterile Dosage Forms, Their Preparation and Clinical Application, 3rd edn, p. 120. Eds S. Turco and R. E. King, Lea and Febiger, Philadelphia, PA, USA, 1987.Google Scholar
- 22.Wasan, K. M., Brazeau, G. A., Keyhani, A., Hayman, A. C., and Lopez-Berestein, G., Antimicrob. Ag. Chemother.37 (1993) 246.Google Scholar
- 25.Zar, J. H., Biostatistical Analysis, 2nd edn. Prentice-Hall International, Englewood Cliffs, N.J., 1984.Google Scholar
- 34.Bayerdorffer, E., Mannes, G. A., Richter, W. O., Ochsenkuhn, T., Seeholzer, G., Kopcke, W., Wiebecke, B., and Paumgartner, G., Ann. inter. Med.118 (1993) 481.Google Scholar
- 37.Wasan, K. M., Grossie, V. B., and Lopez-Berestein, G., Antimicrob. Ag. Chemother.38 (1994) 2224.Google Scholar
- 38.Wasan, K. M., Drugs of the Future19 (1994) 225.Google Scholar
- 39.Wasan, K. M., Rosenblum, M. G., Cheung, L., and Lopez-Berestein, G., Antimicrob. Ag. Chemother.38 (1994) 223.Google Scholar